

In the matter of the Canadian Anti-Doping Program;

And in the matter of an anti-doping rule violation by Martin Prinsloo asserted by the Canadian Centre for Ethics in Sport;

File Outcome Summary

Summary

1. The Canadian Centre for Ethics in Sport (CCES) conducted an In-Competition Sample collection session on March 7, 2025, in Toronto, ON.
2. The Athlete was selected for Doping Control. The Sample provided by the Athlete returned an Adverse Analytical Finding (AAF) for Oxandrolone and metabolites (Oxandrolone), Stanozolol metabolites (Stanozolol) and Testosterone, all non-Specified Substances included on the World Anti-Doping Agency's (WADA) 2025 Prohibited List.
3. Following receipt of the CCES's Notification letter asserting an anti-doping rule violation (ADRV) for the presence and Use of the above-mentioned Prohibited Substances, the Athlete signed an Early Admission and Acceptance of Sanction Form, thereby admitting the ADRV, waiving his right to a hearing and accepting all applicable Consequences.

Jurisdiction

4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada and is responsible for handling the administration of the Canadian Anti-Doping Program (CADP), including providing anti-doping services to national Sport Organizations and their members.
5. As Canada's National Anti-Doping Organization, the CCES is compliant the World Anti-Doping Code ("the Code") and its mandatory International Standards. The CCES has implemented the Code and the International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
6. The Athlete is a member of and participates in the activities of U SPORTS. According to CADP Rule 1.3, the CADP applies to all members of, and Participants in activities of Sport Organizations adopting it. The CADP was issued for adoption by Canadian Sport Organizations on October 26, 2020, to be operational on January 1, 2021. U SPORTS adopted the CADP on January 27, 2021. Therefore, the Athlete is subject to the CADP.

Doping Control

7. On March 7, 2025, the CCES conducted an In-Competition Sample collection session in Toronto, ON. Testing was conducted as part of the CCES's domestic test distribution plan under the CADP.
8. The Athlete was notified that he had been selected for Doping Control and, together with the Doping Control Officer from the CCES, completed the Sample collection process. The

Athlete's Sample code number was 8075834.

Results Management

9. On March 11, 2025, the Athlete's Sample was received for analysis by the INRS Centre Armand-Frappier Santé Biotechnologie ("the INRS"), a World Anti-Doping Agency (WADA) accredited laboratory in Laval, QC.
10. On March 31, 2025, the INRS reported an AAF for Oxandrolone, Stanozolol and Testosterone in the Athlete's Sample.
11. Oxandrolone, Stanozolol and Testosterone are classified as non-Specified Substances on WADA's 2025 Prohibited List and are prohibited at all times.
12. On April 14, 2025, the CCES issued a Notification of a potential ADRV to the Athlete for the presence and Use of Prohibited Substances and imposed a Provisional Suspension pursuant to CADP Rule 7.4.1.
13. On April 16, 2025 and April 21, 2025, the Athlete responded to the CCES's Notification letter with their explanation.
14. In accordance with CADP Rule 10.2.1.1, the standard sanction for a violation involving a non-Specified Substance is a four (4) year period of ineligibility. After assessing the circumstances of this case, the CCES determined that there were Aggravating Circumstances, specifically the Athlete's Use of multiple Prohibited Substances, which justified asserting an additional two (2) year period of Ineligibility pursuant to CADP Rule 10.4.

Confirmation of Violation and Sanction

15. On July 14, 2025, the Athlete signed and submitted the Early Admission and Acceptance of Sanction Form to the CCES and as a result received a one (1) year reduction to their six (6) year period of Ineligibility. Therefore, effective July 14, 2025, an ADRV was confirmed against the Athlete for the presence and Use of the identified Prohibited Substances. In accordance with CADP Rules 10.2.1.1, 10.4 and 10.8.1, the sanction for this violation is a five (5) year period of Ineligibility which, in accordance with CADP Rule 10.13.2.1, commenced on April 14, 2025, the date the Athlete was provisionally suspended, and concludes on April 13, 2030.
16. Further, in accordance with CADP Rules 9, 10.1 and 10.10, any competitive results obtained by the Athlete from date of Sample collection to the date the Athlete was provisionally suspended shall be Disqualified.
17. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 31st day of July 2025.



Kevin Bean
Executive Director, Sport Integrity
CCES